Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies

Daniel M. Hartung, Dennis McCarty, Rongwei Fu, Katharina Wiest, Mady Chalk, David R. Gastfriend

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Through improved adherence, once-monthly injectable extended-release naltrexone (XR-NTX) may provide an advantage over other oral agents approved for alcohol and opioid dependence treatment. The objective of this study was to evaluate cost and utilization outcomes between XR-NTX and other pharmacotherapies for treatment of alcohol and opioid dependence. Published studies were identified through comprehensive search of two electronic databases. Studies were included if they compared XR-NTX to other approved medicines and reported economic and healthcare utilization outcomes in patients with opioid or alcohol dependence. We identified five observational studies comparing 1,565 patients using XR-NTX to other therapies over 6. months. Alcohol dependent XR-NTX patients had longer medication refill persistence versus acamprosate and oral naltrexone. Healthcare utilization and costs was generally lower or as low for XR-NTX-treated patients relative to other alcohol dependence agents. Opioid dependent XR-NTX patients had lower inpatient substance abuse-related utilization versus other agents and $8170 lower total cost versus methadone.

Original languageEnglish (US)
Pages (from-to)113-121
Number of pages9
JournalJournal of Substance Abuse Treatment
Volume47
Issue number2
DOIs
StatePublished - Aug 2014

Keywords

  • Alcohol dependence
  • Naltrexone
  • Opioid dependence

ASJC Scopus subject areas

  • Phychiatric Mental Health
  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies'. Together they form a unique fingerprint.

  • Cite this